Candel Therapeutics (NASDAQ:CADL) Given New $25.00 Price Target at Canaccord Genuity Group

Candel Therapeutics (NASDAQ:CADL) had its target price boosted by Canaccord Genuity Group from $20.00 to $25.00 in a report issued on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price on shares of Candel Therapeutics in a report on Wednesday. Citigroup started coverage on shares of Candel Therapeutics in a research note on Thursday, February 20th. They set a “buy” rating and a $25.00 price objective for the company. Finally, Bank of America initiated coverage on shares of Candel Therapeutics in a report on Friday, February 7th. They issued a “buy” rating and a $15.00 target price for the company.

Candel Therapeutics Stock Performance

Shares of NASDAQ:CADL opened at $8.47 on Wednesday. The company has a market capitalization of $275.07 million, a PE ratio of -4.90 and a beta of -1.25. The stock has a fifty day moving average of $8.37 and a 200-day moving average of $6.72. Candel Therapeutics has a one year low of $1.34 and a one year high of $14.60.

Insider Transactions at Candel Therapeutics

In other Candel Therapeutics news, insider William Garrett Nichols sold 13,935 shares of Candel Therapeutics stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $4.56, for a total transaction of $63,543.60. Following the transaction, the insider now owns 100,547 shares of the company’s stock, valued at $458,494.32. The trade was a 12.17 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CTO Seshu Tyagarajan sold 20,392 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $4.56, for a total transaction of $92,987.52. Following the completion of the sale, the chief technology officer now directly owns 125,657 shares of the company’s stock, valued at $572,995.92. This trade represents a 13.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 75,856 shares of company stock valued at $470,044 over the last quarter. Company insiders own 41.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CADL. Squarepoint Ops LLC lifted its position in Candel Therapeutics by 86.6% in the 4th quarter. Squarepoint Ops LLC now owns 19,311 shares of the company’s stock worth $168,000 after buying an additional 8,962 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in shares of Candel Therapeutics by 3.0% during the fourth quarter. Nuveen Asset Management LLC now owns 68,226 shares of the company’s stock worth $592,000 after acquiring an additional 2,009 shares in the last quarter. Maven Securities LTD purchased a new stake in shares of Candel Therapeutics during the fourth quarter worth $449,000. Millennium Management LLC boosted its position in Candel Therapeutics by 130.6% during the fourth quarter. Millennium Management LLC now owns 31,626 shares of the company’s stock valued at $275,000 after purchasing an additional 17,914 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Candel Therapeutics by 12.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,165 shares of the company’s stock valued at $106,000 after purchasing an additional 1,340 shares in the last quarter. 13.93% of the stock is owned by hedge funds and other institutional investors.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.